S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Novan Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume11.21 million shs
Average Volume5.98 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.
Novan logo


Overall MarketRank

1.26 out of 5 stars

Analyst Opinion: 4.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Novan (VTX:NOVN) Frequently Asked Questions

Is Novan a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 sell ratings, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novan stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares.
View analyst ratings for Novan
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novan?

Wall Street analysts have given Novan a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novan wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for NOVN?

13 brokers have issued 12 month target prices for Novan's stock. Their forecasts range from CHF 75 to CHF 109. On average, they expect Novan's stock price to reach CHF 94.08 in the next year.
View analysts' price targets for Novan
or view Wall Street analyst' top-rated stocks.

Who are some of Novan's key competitors?

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Novartis (NVS), General Motors (GM), IAMGOLD (IAG), (DGI) (DGI), The Walt Disney (DIS), Bank of America (BAC), The Coca-Cola (KO), Merck & Co., Inc. (MRK), NovaGold Resources (NG) and NIKE (NKE).

Who are Novan's key executives?

Novan's management team includes the following people:
  • Ms. Paula Brown Stafford, Pres, CEO & Chairwoman (Age 55, Pay $450.48k)
  • Mr. John M. Gay, Chief Financial Officer (Age 44, Pay $255.81k)
  • Mr. Robert Alexander Ingram, Exec. Director (Age 78, Pay $70k)
  • Mr. Andrew J. Novak, VP of Accounting & Bus. Operations and Chief Accounting Officer
  • Dr. Carri Geer, Sr. VP & CTO
  • Cole Ikkala, Director of Investor Relations, Communications & Bus. Devel.
  • Mr. Stanley Hollenbach BS, J.D., Sr. VP of R&D
  • Ms. Elizabeth Messersmith, Sr. VP & Chief Devel. Officer

What is Novan's stock symbol?

Novan trades on the VTX under the ticker symbol "NOVN."

What is Novan's official website?

The official website for Novan is www.novartis.com.

How can I contact Novan?

Novan's mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.